WCM Investment Management LLC Reduces Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

WCM Investment Management LLC reduced its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 0.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 127,577 shares of the medical equipment provider’s stock after selling 497 shares during the quarter. WCM Investment Management LLC owned 0.18% of Lantheus worth $11,371,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in LNTH. Geode Capital Management LLC grew its position in shares of Lantheus by 2.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock valued at $184,798,000 after acquiring an additional 32,551 shares during the period. Moloney Securities Asset Management LLC purchased a new position in shares of Lantheus in the third quarter valued at approximately $1,066,000. Massachusetts Financial Services Co. MA acquired a new stake in Lantheus during the 3rd quarter worth $25,955,000. Van ECK Associates Corp boosted its position in Lantheus by 58.6% during the third quarter. Van ECK Associates Corp now owns 58,472 shares of the medical equipment provider’s stock worth $6,469,000 after acquiring an additional 21,604 shares during the last quarter. Finally, Empirical Asset Management LLC acquired a new position in shares of Lantheus during the 4th quarter worth approximately $323,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Price Performance

Shares of LNTH opened at $88.71 on Monday. The firm has a 50-day simple moving average of $92.08 and a two-hundred day simple moving average of $98.64. The stock has a market cap of $6.17 billion, a PE ratio of 14.76 and a beta of 0.44. Lantheus Holdings, Inc. has a 1-year low of $53.47 and a 1-year high of $126.89.

Analyst Ratings Changes

LNTH has been the subject of several analyst reports. JMP Securities restated a “market outperform” rating and issued a $112.00 target price on shares of Lantheus in a report on Tuesday, January 14th. Truist Financial restated a “buy” rating and set a $120.00 price objective (down from $135.00) on shares of Lantheus in a research report on Friday, November 8th. The Goldman Sachs Group initiated coverage on shares of Lantheus in a report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 target price on the stock. Finally, StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, Lantheus presently has an average rating of “Moderate Buy” and a consensus price target of $131.86.

Insider Buying and Selling

In other Lantheus news, Director James H. Thrall sold 1,000 shares of the company’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the transaction, the director now directly owns 33,207 shares in the company, valued at $3,146,695.32. This represents a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.50% of the stock is currently owned by corporate insiders.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.